Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Person › Details

Peter Amersdorfer (Lacerta Technologies GmbH)

Amersdorfer, Peter (Lacerta Technologies GmbH 201401– CBO before Oridis Biomed 200705 Head BusDev)

 

Organisations Organisation Lacerta Technologies GmbH
  Today OrthoSera GmbH
  Group OrthoSera (Group)
  Former/major organisation Oridis Biomed Forschungs- und Entwicklungs GmbH
  Today Oridis Biomarkers GmbH
  Group Oridis Biomarkers GmbH
Product Product tissue engineering / regenerative medicine
     

Lacerta Technologies GmbH. (1/30/14). "Press Release: New Chief Business Officer at Lacerta Technologies GmbH". Krems an der Donau.

Lacerta Technologies has hired a new Chief Business Officer to strengthen the senior management team and to support the ramping up of the company's clinical development and commercialization efforts.

With more than 15 years of experience in the healthcare industry Dr. Peter Amersdorfer has played a significant role in the development and execution of R&D and business development strategies for several start-up companies both in the US and Europe. His position with Lacerta Technologies has been newly established and will enable the Krems based regenerative medicine company to bring its products to the international market. The new serum coated bone graft products and related technologies are aimed for orthopaedic, dental or sports surgery use.

"Dr. Amersdorfer represents a critical addition to the team at this pivotal point in the company's transition from an R&D focus towards a more product- and market-driven approach," comments Dr. Zsombor Lacza, CEO of Lacerta Technologies. "Peter brings considerable industry experience that will boost our abilities to build and advance our product pipeline and identify new markets for Lacerta's technologies."


Profile Lacerta Technologies GmbH

Founded in 2012 and located in Krems an der Donau/Austria Lacerta Technologies GmbH is a clinicalstage regenerative medicine company aiming to translate research results into products for routin clinical use. We put special emphasis on designing simple and affordable protocols allowing a wider patient population to benefit from cell therapy.

Our current development projects include an innovative albumin-coated bone allograft and a point-ofcare device for the personalised production of autologous serum products.


Contact information

Lacerta Technologies GmbH
Dr.-Karl-Dorrek-Straße 23-29
A-3500 Krems an der Donau
Tel/Fax: +43 664 77 883 16206
Email: marion.ettenauer@lacertatech.com
www.lacertatechnologies.com

   
Record changed: 2017-04-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px


More documents for Peter Amersdorfer


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px




» top